Scopus BioPharma (Scopus BioPharma) Cash-to-Debt

: No Debt ⁽¹⁾ (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Scopus BioPharma's cash to debt ratio for the quarter that ended in Jun. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Scopus BioPharma could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Scopus BioPharma's Cash-to-Debt or its related term are showing as below:

SCPS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: No Debt Max: No Debt
Current: No Debt

During the past 6 years, Scopus BioPharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was No Debt.

SCPS's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs SCPS: No Debt

Scopus BioPharma Cash-to-Debt Historical Data

The historical data trend for Scopus BioPharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Scopus BioPharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

No Debt

0.80

No Debt

Scopus BioPharma Quarterly Data
	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt																No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison

For the Biotechnology subindustry, Scopus BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's Cash-to-Debt falls into.

Scopus BioPharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Scopus BioPharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Scopus BioPharma had no debt ⁽¹⁾.

Scopus BioPharma's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Scopus BioPharma had no debt ⁽¹⁾.

Scopus BioPharma (OTCPK:SCPS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Scopus BioPharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Scopus BioPharma (Scopus BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website

https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

Executives

Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein	director, officer: Chairman	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager	officer: See Remarks	1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson	director, officer: Vice Chairman	71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Iv David Weild	director	22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel	director	SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein	director	C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper	director	7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka	director, officer: President	101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005